Orforglipron vs Injectable GLP-1 Peptides: The Oral Route Won on Convenience and Lost on Tolerability

Orforglipron is a tablet, not a peptide. FDA approved it for obesity on 1 April 2026, and it took off 12.4% of body weight in its pivotal trial — less than the injectable peptides, in trials nobody designed to be compared.

The trade-off this page resolves is route against everything else: a swallowed tablet with a prescription behind it, versus an injectable peptide that either needs a prescription you may not have or arrives in a grey-market vial. The fact base supports that framing in places and undercuts it in others, and both halves are below. All three compounds sit in the weight loss and metabolic peptides category, and the injectable trial records are in semaglutide: the nausea rate is 44.2%, not 73% and tirzepatide: the dual GIP/GLP-1 agonist that beat semaglutide by 6.5 points.

What is the actual difference between orforglipron and the injectable GLP-1 peptides?

Orforglipron is a non-peptide small molecule — Lilly's own description is a "once-daily small molecule (non-peptide) oral glucagon-like peptide-1 receptor agonist" — with a free-acid molecular weight of 883.0 g/mol. Semaglutide is a 31-amino-acid peptide at 4,113.6 g/mol, and tirzepatide a 39-residue peptide at 4,813.0 g/mol. All three agonise the GLP-1 receptor. Only two of the three are peptides, and that single fact decides the route, the manufacturing and the verification problem.

The class label is the first thing most write-ups get wrong. Orforglipron is not a peptide, and calling it one is not a pedantic distinction — it is the reason the drug can be swallowed. A 4,113 dalton peptide is digested; an 883 dalton small molecule is not, which is why semaglutide's oral form needs an absorption enhancer and a fasted stomach while orforglipron does not.

The identity record is otherwise straightforward. The active moiety is orforglipron calcium, formula C48H47F2N10O5·[0.5]Ca at MW 902.0 for the calcium salt, with the free acid at C48H48F2N10O5, MW 883.0, CAS 2212020-52-3, developed by Eli Lilly under the codes LY3502970 and OWL833. We could not verify a PubChem CID for orforglipron, so we are not printing one — the CAS number and the label formula are what the record supports. Vendor-level detail for the two peptides sits on the semaglutide compound page and the tirzepatide compound page.

Which takes off more weight, and has anyone run them head to head?

Orforglipron produced 12.4% weight loss at 72 weeks in ATTAIN-1 (n=3,127) on the efficacy estimand, against −0.9% on placebo, p<0.001 at all three doses on the treatment-regimen estimand. Semaglutide's STEP 1 figure is −14.9% and tirzepatide's SURMOUNT-1 figure is −20.9%. No trial has compared orforglipron against tirzepatide, and none has compared it against injectable semaglutide. Placing those numbers side by side is cross-trial arithmetic, not a head-to-head.

ATTAIN-1 is Wharton, Aronne, Stefanski and colleagues in the New England Journal of Medicine, 2025 (PMID 40960239, NCT05869903), randomised 3:3:3:4 across three doses and placebo. Responder rates at the top dose on the efficacy estimand were 77.1% losing at least 5% of body weight, 59.6% at least 10%, 39.6% at least 15% and 20.1% at least 20%, against 22.1%, 8.6%, 3.6% and 1.6% on placebo.

The dose numbers in ATTAIN-1 are not the dose numbers on the bottle, and this is the single most common error in circulation. The phase 3 programme used a capsule; the marketed product is a tablet, and the two are not interchangeable milligram for milligram. The 36 mg capsule corresponds to the 17.2 mg tablet, 12 mg to 9 mg, and 6 mg to 5.5 mg. The FDA label restates the ATTAIN-1 arms as 5.5, 9 and 17.2 mg and never mentions 6, 12 or 36 mg anywhere. The marketed maximum is 17.2 mg. Anyone writing "the top dose is 36 mg" is quoting a capsule that is not sold.

The cross-trial confounds are the usual ones and they are not small. ATTAIN-1, STEP 1 and SURMOUNT-1 ran in different populations, over 72, 68 and 72 weeks, with placebo arms losing 0.9%, 2.4% and 3.1% respectively, and orforglipron reports two estimands where the older trials report one. A 12.4% result read against a −0.9% placebo is not the same measurement as a 14.9% result read against −2.4%. The direction of the gap is consistent across every comparison available; the size of it is an estimate.

What did ACHIEVE-3 settle, and what did it leave open?

ACHIEVE-3 is the only head-to-head orforglipron has, and it ran against oral semaglutide only. In 1,698 patients with type 2 diabetes over 52 weeks, orforglipron beat oral semaglutide 14 mg on both endpoints at p<0.001 — HbA1c −2.2% versus −1.4%, weight −9.2% versus −5.3%. It also lost on tolerability: adverse-event discontinuation ran 9.7% on orforglipron against 4.9% on oral semaglutide. The trial was open-label.

The trial is Rosenstock, Yabe, Cox and colleagues in The Lancet, 2026 (PMID 41765029, NCT06045221). Three qualifications travel with it, and none of them is optional.

It was open-label. Patients and investigators knew which drug they were taking, in a trial whose secondary endpoints include weight and whose safety endpoints include self-reported gastrointestinal symptoms. That design cannot be blinded easily when one arm has a fasting protocol and the other does not, but it is a real limitation on soft endpoints.

The comparator was the oral tablet, not the injection. Oral semaglutide 14 mg is not the 2.4 mg weekly injection that produced −14.9% in STEP 1, and it is not the 7.2 mg dose that produced −20.7% in STEP UP. Beating oral semaglutide is not beating semaglutide.

Orforglipron was worse on tolerability, and by roughly double. A 9.7% against 4.9% discontinuation rate is the finding most summaries leave out, and it points the same way as ATTAIN-1, where discontinuation for adverse events ran 5.3%, 7.9% and 10.3% across the three doses against 2.7% on placebo, with nausea at 33.7% versus 10.4% and vomiting at 24.0% versus 3.5%. No trial of orforglipron against tirzepatide exists, and nothing in the record supports a claim in either direction there.

Which is easier to actually take?

Orforglipron wins this axis outright, and it is the clearest win on the page. The label instruction is to "take FOUNDAYO orally once daily, with or without food" and to "swallow tablets whole" — no fasting window, no water restriction, no waiting period, no needle, no reconstitution. Oral semaglutide carries all four of the restrictions orforglipron does not, and the injectables carry a weekly injection plus, outside a pharmacy, a reconstitution step of their own.

The oral semaglutide restrictions are worth reading verbatim, because they are what the tablet comparison is actually about. The label requires dosing "on an empty stomach in the morning with water (up to 4 ounces of water)", instructs "do not take … with other liquids besides water", and directs the patient to "wait at least 30 minutes before eating food, drinking beverages or taking other oral medications". Orforglipron has none of these. Absolute bioavailability is 77% at the 0.8 mg dose, which is the pharmacological reason the fasting protocol is unnecessary rather than merely inconvenient.

That convenience is real and it should not be oversold either. Orforglipron is dosed daily against a weekly injection, so the number of administration events per year runs 365 against 52. Whether a daily tablet or a weekly needle is the lower burden is a preference, not a finding. For anyone converting an injectable dose into an injection volume, the semaglutide calculator and tirzepatide calculator sit alongside the reconstitution calculator, and the strength conversions are in the semaglutide dosing chart and the tirzepatide dosing guide.

Does an approved tablet come with fewer warnings than an unapproved vial?

No, and orforglipron's warning set is the most interesting document in this comparison. It carries a boxed warning for thyroid C-cell tumours even though, in the label's own words, "orforglipron is not pharmacologically active in rats or mice and did not produce tumors in rodents". Semaglutide and tirzepatide carry the same boxed warning because of rodent tumour findings. Orforglipron carries it in their absence, as a class warning applied on receptor logic rather than on its own animal data.

The label's full reasoning is worth quoting, because it explains a warning that would otherwise look like an error: "While orforglipron is pharmacologically active at the human GLP-1 receptor, the human relevance of GLP-1 receptor-dependent thyroid C-cell tumors observed in rodents has not been determined." The agency has, in effect, declined to treat a negative rodent carcinogenicity result as reassurance, because the negative result may only mean the drug does not engage the rodent receptor. It is contraindicated in personal or family history of medullary thyroid carcinoma or MEN 2, the same contraindication both peptides carry.

The nine warnings and precautions at sections 5.1 through 5.9 cover thyroid C-cell tumours, acute pancreatitis, severe gastrointestinal reactions, acute kidney injury, hypoglycaemia, hypersensitivity, diabetic retinopathy complications, acute gallbladder disease and pulmonary aspiration under anaesthesia. There is no REMS, which means the warnings are managed by labelling rather than by a restricted distribution programme.

The postmarketing requirements are the part that deserves more attention than the boxed warning. FDA required a cardiovascular outcomes and drug-induced liver injury safety trial, a 15-year medullary thyroid carcinoma registry, pregnancy registries, and five years of enhanced pharmacovigilance for drug-induced liver injury. A five-year enhanced liver-injury programme is not a routine condition of approval. It is a statement that the agency approved on the efficacy and reserved judgment on a specific organ. Cross-compound adverse-event context is in the peptide side effects hub.

Which is legal, and which route actually exists?

Orforglipron is an approved prescription medicine in the United States under NDA 220934, ORIG-1, a Type 1 new molecular entity approved on 1 April 2026 with sponsor Eli Lilly, and its indication is obesity only — it is not approved for type 2 diabetes. Semaglutide and tirzepatide are approved prescription medicines with broader indication sets. All three therefore have a legitimate prescription route, which is the half of the tablet-versus-vial framing that does not hold.

The indication reads, verbatim: "FOUNDAYO is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition." That is the whole approved scope. The US type 2 diabetes submission was still described as planned as of February 2026, so ACHIEVE-1 and ACHIEVE-3 are trial evidence in an indication the drug does not hold. A supplement, SUPPL-3, added a Medication Guide on 4 August 2026.

The compounding pathway that once supplied a great deal of injectable GLP-1 material is shut for both peptides. FDA declared the semaglutide injection shortage resolved on 21 February 2025, with enforcement discretion ending 22 April 2025 for 503A pharmacies and 22 May 2025 for 503B outsourcing facilities, and the shortage database now lists Tirzepatide Injection as "Resolved". Compounding an essentially-a-copy product was permitted only during shortage; the shortage was the permission. See the FDA peptide regulation timeline, compounding pharmacy versus research peptide and can you get semaglutide without a prescription.

On sport, we are printing only what we hold. Semaglutide and tirzepatide are absent from the WADA 2026 Prohibited List, semaglutide has been on the Monitoring Program since 2024, and from 1 January 2026 markers of both are monitored in and out of competition. Our fact base records no WADA entry for orforglipron in either direction, so we are not stating one. Absence from our record is not absence from the list.

Which is harder to verify, and what does each cost?

This is the axis where the tablet-versus-vial framing holds completely. A prescription orforglipron tablet dispensed by a pharmacy has no identity, quantity or sterility problem to solve. A research-market GLP-1 vial has all three. Tirzepatide averages 99.75% purity across 930 independent tests (verified August 2026) and still runs +2.6% to +26.7% over label on fill quantity, while semaglutide's characteristic failures are salt-form substitution and underdosing.

The two peptides fail in opposite directions, which is why one checklist does not cover both.

Tirzepatide's problem is quantity. The Purity Index records 99.75% average purity across 930 independent tests from five laboratories — Freedom Diagnostics, Kovera, ILS, Accumark and MZ Biolabs — across 227 shops selling (verified August 2026). Identity is broadly reliable. Vials labelled 10 to 65 mg have tested between 10.71 and 68.1 mg. On a drug titrated in 2.5 mg steps, a 26.7% overage is a dosing error, and it runs in the direction that produces the nausea and vomiting people discontinue for.

Semaglutide's problem is identity. FDA states that semaglutide sodium and semaglutide acetate "are different active ingredients than are used in the approved drugs" and that the agency "does not have information on whether these salts have the same chemical and pharmacologic properties." A vial of a salt form can return a genuine 99% purity figure and be 99% pure of something no randomised trial tested. Semaglutide's own per-compound purity average and test count are read live from the Purity Index and the price page rather than printed here, because a figure we cannot date is worth less than a page you can refresh.

Peptigrity's platform currently tracks 530 shops and 11,852 independent lab tests across 118 peptides, with 1,283 community reviews (verified August 2026). Trust scores weight community reviews and independently verified HPLC purity equally at 50% each, with no financial relationship influencing the ranking. Tirzepatide price data shows 14 shops in stock, a median of $5.67/mg and a lowest tracked price of $1.17/mg on a 60 mg vial (verified August 2026), across 48 compared offers from $19.99 to $465.00. Semaglutide price data shows 8 shops in stock, a median of $9.00/mg and a lowest tracked price of $3.00/mg on a 10 mg vial (verified August 2026), across 20 offers from $29.99 to $300.00. We hold no Purity Index entry and no price data for orforglipron, which is itself the finding: it is a pharmacy product, not a research-market one. Those figures exclude shipping, taxes and customs, coupon codes, bulk tiers, multi-vial kits and account-gated pricing.

Per-milligram price is close to meaningless across these three, because a 17.2 mg daily tablet, a 2.4 mg weekly injection and a 15 mg weekly injection are not comparable quantities of drug. Convert to cost per dose with the cost-per-dose calculator before comparing anything. The compound-specific walkthroughs are in where to buy semaglutide and where to buy tirzepatide, with why 10 mg isn't 10 mg, TFA vs acetate vs amidate peptide salt forms and mass spectrometry for peptides covering the failure modes. Individual results are searchable in the lab test database.

So which should you choose?

For maximum weight loss, the injectable peptides, and the margin is wide enough to survive the cross-trial caveat — −20.9% and −14.9% against orforglipron's −12.4%. For avoiding needles, reconstitution and a fasting protocol, orforglipron, uncontested. For tolerability, semaglutide and tirzepatide, on 4.5% and 4.3–7.1% discontinuation against orforglipron's 10.3%. For type 2 diabetes, not orforglipron, which has the trial data and not the indication.

The trial that would settle this

No trial has compared orforglipron with an injectable GLP-1 peptide. ACHIEVE-3 compared it with oral semaglutide 7 and 14 mg, open-label, in 1,698 patients with type 2 diabetes over 52 weeks — a different formulation, a different population and a different endpoint from the obesity comparison most readers want. The study that would resolve this page is a blinded randomised trial of orforglipron 17.2 mg against injectable semaglutide 2.4 mg and tirzepatide 15 mg, in obesity, with discontinuation as a co-primary endpoint.

Frequently Asked Questions

Is orforglipron a peptide?

No. It is a non-peptide small molecule, described by Eli Lilly as a "once-daily small molecule (non-peptide) oral glucagon-like peptide-1 receptor agonist" and titled the same way in its NEJM publication. Its free acid weighs 883.0 g/mol against semaglutide's 4,113.6 and tirzepatide's 4,813.0. That size difference is exactly why it survives digestion and they do not.

What is the highest orforglipron dose?

17.2 mg once daily. The strengths are 0.8, 2.5, 5.5, 9, 14.5 and 17.2 mg, starting at 0.8 mg with escalation no sooner than every 30 days. The 36 mg figure circulating online is the phase 3 capsule dose, and the capsule and tablet are not equivalent milligram for milligram — 36 mg capsule corresponds to 17.2 mg tablet. The FDA label never mentions 6, 12 or 36 mg.

Does orforglipron work as well as tirzepatide?

Nobody knows, because no trial has compared them. Orforglipron produced 12.4% weight loss at 72 weeks in ATTAIN-1 and tirzepatide produced 20.9% at 72 weeks in SURMOUNT-1, but those are separate trials in separate populations with placebo arms losing 0.9% and 3.1% respectively. The direction is consistent; the size is an estimate.

Why does orforglipron have a boxed warning if it caused no tumours in rodents?

Because the rodent result may not mean what it appears to. The label states orforglipron "is not pharmacologically active in rats or mice and did not produce tumors in rodents", then applies the class warning anyway on the grounds that "the human relevance of GLP-1 receptor-dependent thyroid C-cell tumors observed in rodents has not been determined". A negative result in an animal the drug does not engage is not reassurance.

Is orforglipron easier to take than oral semaglutide?

Substantially. Orforglipron is taken with or without food and swallowed whole, with no fluid restriction and no waiting period. Oral semaglutide must be taken on an empty stomach in the morning with up to four ounces of water, no other liquids, and at least 30 minutes before eating, drinking or taking other oral medicines. Orforglipron has none of those constraints.

Can you buy orforglipron on the research market?

We hold no Purity Index entry, lab tests or price data for orforglipron, and no research-market listings appear in our fact base for it. It is a prescription tablet under NDA 220934, approved 1 April 2026 for obesity. That is a genuine difference from the injectable peptides, whose grey-market supply is extensive and whose failure modes are salt substitution, underdosing and fill overage to +26.7%.

Where this leaves the choice

The tablet-versus-vial framing is half right. Orforglipron removes the needle, the reconstitution, the fasting protocol and the entire verification problem — no mass spectrometry, no salt-form question, no fill-accuracy risk — because a dispensed tablet is an approved product rather than a vial of unknown provenance. On convenience and supply integrity it wins without argument. On weight loss it lands at 12.4% against 14.9% and 20.9%, cross-trial, and on adverse-event discontinuation at 10.3% against 4.5% and 4.3–7.1%.

It loses on almost everything else too. The 9.7% against 4.9% discontinuation gap in the only head-to-head orforglipron has was measured against a tablet rather than an injection, in an open-label trial, in patients with type 2 diabetes rather than obesity. Its approval arrived with a boxed warning it carries without rodent tumours behind it, nine sections of warnings and precautions, and five years of enhanced liver-injury pharmacovigilance attached as a condition.

The other half of the framing does not hold at all. Semaglutide and tirzepatide are also approved prescription medicines with legitimate routes; the grey market is a choice some buyers make, not a property of the molecules. The honest statement of the trade-off is narrower than the usual one: orforglipron trades roughly two to eight percentage points of weight loss, and roughly double the discontinuation rate, for a tablet you can swallow with breakfast.

Browse the weight loss and metabolic peptides category, or our complete peptide guide with 118 compounds (verified August 2026). For per-injection volume, use the semaglutide calculator or the tirzepatide calculator alongside the reconstitution calculator. Compare shops through independent lab tests and community-verified shop reviews.

This article is for educational and informational purposes only and does not constitute medical advice. Peptides discussed may be investigational compounds not approved by the FDA (or equivalent regulators in your jurisdiction) for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.